# Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

> **NCT05651672** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Gastrointestinal Cancer

## Interventions

- **DRUG:** Pemigatinib

## Key facts

- **NCT ID:** NCT05651672
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-02
- **Primary completion:** 2024-12
- **Final completion:** 2026-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05651672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05651672, "Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05651672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*